Azacitidine-associated Sweet's syndrome.
Purpose. Sweet's syndrome (also known as acute febrile neutrophilic dermatosis) in two patients receiving azacitidine therapy is reported. Summary. The development of Sweet's syndrome in association with azacitidine use is rare (three published case reports since the drug's U.S. marketing approval i...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 69; no. 10; pp. 869 - 872 |
|---|---|
| Autores principales: | , , |
| Formato: | case study Journal Article |
| Publicado: |
Oxford University Press / USA
5/15/2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104445856&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104445856 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10792082 1X3 jtl: American Journal of Health-System Pharmacy issn: 10792082 maglogo: N pubinfo: dt: 5/15/2012 vid: 69 iid: 10 pid: 622 pub: Oxford University Press / USA artinfo: ui: 104445856 75128033 10.2146/ajhp110523 NLM22555082 104445856 ppf: 869 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Azacitidine-associated Sweet's syndrome. aug: au: Trickett, Hannah B. Cumpston, Aaron Craig, Michael affil: Clinical Pharmacist, Department of Pharmaceutical Services, West Virginia University (WVU) Healthcare, Morgantown sug: subj: Azacitidine Administration and Dosage Azacitidine Adverse Effects Myelodysplastic Syndromes Diagnosis Myelodysplastic Syndromes Drug Therapy Sweet's Syndrome Chemically Induced Sweet's Syndrome Drug Therapy Aged Amoxicillin Therapeutic Use Exanthema Chemically Induced Fever Chemically Induced Male Methylation Drug Effects Middle Age Prednisone Therapeutic Use Treatment Outcomes Aged: 65+ years Middle Aged: 45-64 years Male ab: Purpose. Sweet's syndrome (also known as acute febrile neutrophilic dermatosis) in two patients receiving azacitidine therapy is reported. Summary. The development of Sweet's syndrome in association with azacitidine use is rare (three published case reports since the drug's U.S. marketing approval in 2004), and the syndrome is not listed as a potential adverse reaction in the product packaging. In one of two cases of probable azacitidine-related Sweet's syndrome reported here, a 64-year-old man with myelodysplastic syndrome (MDS) developed a severe erythematous and nodular rash with peeling on his arms, legs, and face after receiving the drug (75 mg/m2 subcutaneously daily) for three days; the second case involved a 67-year-old man with chronic myelomonocytic leukemia (CMML) who experienced a similar skin rash, as well as chills and an elevated body temperature, after five days of treatment with azacitidine. In both cases, the results of dermatologic or pathologic examination and skin biopsies were consistent with Sweet's syndrome. Perhaps the strongest evidence of a drug-induced etiology in these cases was the close temporal relationship between the initiation of azacitidine use and the development of Sweet's syndrome, with prompt symptom resolution after the discontinuation of azacitidine use and administration of appropriate corticosteroid therapy. Conclusion. Azacitidine was the apparent cause of Sweet's syndrome in a patient with MDS and another with CMML. Both responded well to corticosteroid therapy. After resolution of the reaction, decitabine was given to the first patient and azacitidine to the second, without complications. pubtype: Academic Journal doctype: case study Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|